Institutional strategies as a mechanism to rationalize the negative effects of the judicialization of access to medicine in Brazil

Table 6 Plaintiffs’ incomes, cost of medicines of the lawsuits, origin of the prescription and classification of medicines in the lawsuits in periods before and after the deployment of the Department of Assessment of Non-Standardized Medicines (DAMNP) and Technical Chamber of Health Assessment (CATS)

Variables	DAMNP (2006)			CATS (2009)
Variables	Before deployment (2003–2005)	After deployment (2007–2015)	p	Before deployment (2003–2008)	After deployment (2010–2015)	p
Income of Plaintiffs
Mean (SD)¹	1231.4 (858.7)	1458.2 (1182.8)	0.009³	1393.4 (999.8)	1458.2 (1215.2)	0.575³
Median (IQR)²	1004.5 (680.5–1263.8)	1137.8 (680.5–1263.8)		1004.5 (680.5–1263.8)	972.1 (680.5–1263.8)
Cost of medicines in the lawsuit
Mean (SD)¹	1.661.1 (4.561.7)	779.2 (1.589.6)	0.005³	1.884.1 (5.054.8)	586.7 (1.640.3)	< 0.001³
Median (IQR)²	659.7 (188.6–1622.1)	285.6 (101.0–195.8)		541.1 (191.6–1759.4)	250.3 (94.5–616.3)
Prescription’s origin, n (%)
Prescribed by a SUS clinician	20 (25.6)	38 (31.4)	0.382⁴	46 (22.4)	24 (43.6)	0.002⁴
Prescribed by a private system clinician	58 (74.4)	83 (68.6)		159 (77.6)	31 (56.4)
Classification of medicines, n (%)
Within the SUS formulary	261 (47.7)	281 (41.8)	0.039⁴	548 (49.5)	104 (41.1)	0.020⁴
Outside the SUS formulary with a therapeutic alternative	145 (26.5)	217 (32.3)	0.028⁴	289 (26.1)	94 (37.2)	< 0.001⁴
Outside the SUS formulary without a therapeutic alternative	141 (25.8)	174 (25.9)	0.963⁴	271 (24.4)	554 (21.7)	0.360⁴

¹Standard deviation; ²Interquartile range; ³Mann-Whitney Test; ⁴Pearson’s chi-squared test

ISSN: 1472-6963